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Summary
Background Every year, 2·9 million newborn babies die worldwide. A meta-analysis of four cluster-randomised 
controlled trials estimated that home visits by trained community members in programme settings in Ghana and 
south Asia reduced neonatal mortality by 12% (95% CI 5–18). We aimed to estimate the costs and cost-eﬀ ectiveness of 
newborn home visits in a programme setting.
Methods We prospectively collected detailed cost data alongside the Newhints trial, which tested the eﬀ ect of a home-
visits intervention in seven districts in rural Ghana and showed a reduction of 8% (95% CI –12 to 25%) in neonatal 
mortality. The intervention consisted of a package of home visits to pregnant women and their babies in the ﬁ rst week 
of life by community-based surveillance volunteers. We calculated incremental cost-eﬀ ectiveness ratios (ICERs) with 
Monte Carlo simulation and one-way sensitivity analyses and characterised uncertainty with cost-eﬀ ectiveness planes 
and cost-eﬀ ectiveness acceptability curves. We then modelled the potential cost-eﬀ ectiveness for baseline neonatal 
mortality rates of 20–60 deaths per 1000 livebirths with use of a meta-analysis of eﬀ ectiveness estimates.
Findings In the 49 zones randomly allocated to receive the Newhints intervention, a mean of 407 (SD 18) community-
based surveillance volunteers undertook home visits for 7848 pregnant women who gave birth to 7786 live babies in 
2009. Annual economic cost of implementation was US$203 998, or $0·53 per person. In the base-case analysis, the 
Newhints intervention cost a mean of $10 343 (95% CI 2963 to –7674) per newborn life saved, or $352 (95% CI 
104 to –268) per discounted life-year saved, and had a 72% chance of being highly cost eﬀ ective with respect to 
Ghana’s 2009 gross domestic product per person. Key determinants of cost-eﬀ ectiveness were the discount rate, 
protective eﬀ ectiveness, baseline neonatal mortality rate, and implementation costs. In the scenarios modelled with 
the meta-analysis results, the ICER increased from $127 per life-year saved at a neonatal mortality rate of 60 deaths 
per 1000 livebirths, to $379 per life-year saved at a rate of 20 deaths per 1000 livebirths. The strategy had at least a 99% 
probability of being highly cost eﬀ ective for lower-middle-income countries in all neonatal mortality rate scenarios 
modelled, and at least a 95% probability of being highly cost eﬀ ective for low-income countries at neonatal mortality 
rates of 30 or more deaths per 1000 livebirths.
Interpretation Our ﬁ ndings show that the seemingly modest mortality reductions achieved by a newborn home-visit 
strategy might in fact be cost eﬀ ective. In Ghana, such strategies are also likely to be aﬀ ordable. Our ﬁ ndings support 
recommendations from WHO and UNICEF that low-income and middle-income countries implement newborn 
home visits.
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Introduction
Every year, 2·9 million newborn babies die worldwide; 
98% of these deaths are in low-income or middle-income 
countries.1 Existing interventions and care practices could 
prevent most of these deaths.2 Saving newborn lives thus 
presents a health-systems challenge requiring cost-
eﬀ ective strategies to connect babies with the care and 
interventions proven to protect and restore their health.
Four initial proof-of-principle3 studies in south Asia 
showed that training of lay community health workers to 
do three home visits in the ﬁ rst week of life to promote 
essential newborn care practices and identify and refer or 
treat sick babies could reduce neonatal mortality by up to 
60%.4–7 These studies contributed to the decision by 
WHO and UNICEF to issue a joint statement in 2009 
exhorting all low-income and middle-income countries to 
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implement a home-visit strategy for newborns.8 However, 
in 2013, a meta-analysis of four more recent cluster-
randomised controlled trials estimated a more modest 
12% (95% CI 5–18) reduction in the neonatal mortality 
rate in programme settings.3 One of the four more recent 
trials—Newhints—was done on a large scale in rural 
Ghana in 2007–09 (appendix) and estimated an 8% 
(95% CI –12 to 25; p=0·405) reduction in neonatal 
mortality rate.3 Since 2000, Ghana has been scaling up the 
community-based health planning and services initiative.9 
This scale-up involved a cadre of salaried nurses deployed 
as community health oﬃ  cers who were supported by 
village health committees and unpaid community-based 
surveillance volunteers.10,11 There was no minimum 
education requirement for community-based surveillance 
volunteers, whose role focused on birth and death 
registration and disease surveillance.10,11 Newhints built 
on this existing group of community-based surveillance 
volunteers by providing them with additional training 
and supervision to enable them to expand their role to 
include prenatal and postnatal home visits.
As in the other three more recent cluster-randomised 
trials, Newhints was underpowered to detect statistically 
signiﬁ cant reductions in neonatal mortality rate at the 
levels recorded. Yet, despite diﬀ erences in existing health 
systems, qualiﬁ cations of home visitors, visit content, and 
other aspects of the home-visit packages, there was no 
evidence of heterogeneity in eﬀ ectiveness between the 
four trials in programme settings (p=0·85), and together 
they had suﬃ  cient power.3 Newhints also showed 
statistically signiﬁ cant improvements in the coverage of 
many essential newborn care practices that were targeted 
in the strategy and expected to improve health outcomes.3 
Findings from Newhints were therefore entirely 
consistent with those from the studies in south Asia and 
those from the meta-analysis, which summarised the 
evidence for newborn home-visit eﬀ ectiveness and 
reported that a newborn home-visit strategy can achieve 
small but signiﬁ cant reductions in neonatal mortality.
In view of the seemingly modest eﬀ ect of newborn 
home visits at scale and WHO’s further recommendation 
in 2014 in favour of home visits for postnatal care,12 
evidence about the cost-eﬀ ectiveness of a newborn home-
visit strategy is particularly important to inform policy 
makers about whether this approach is likely to be an 
eﬃ  cient use of resources. Such economic evidence is 
especially relevant in Ghana, where, after the Newhints 
trial, the Newhints strategy was expanded to the control 
areas and nationwide expansion is already underway. Of 
the two economic evaluations of home-visit strategies to 
date, the ﬁ rst provided some incomplete evidence from 
an early non-randomised study in India,13 whereas the 
second evaluated a study in Bangladesh in which the 
protective eﬃ  cacy point estimate was far higher (28%)14 
than in more recent studies.
We aimed to estimate the cost and cost-eﬀ ectiveness of 
the Newhints strategy in rural Brong Ahafo Region in 
Ghana, to model the potential cost-eﬀ ectiveness in 
settings with a range of baseline neonatal mortality rates 
with use of a meta-analysis of eﬀ ectiveness estimates, 
and to compare the incremental cost-eﬀ ectiveness ratios 
(ICERs) with several standard thresholds and with 
currently implemented interventions. We also compared 
our ﬁ ndings with the cost-eﬀ ectiveness of other 
community-based newborn health strategies.
Methods
Study design
Details of the study setting, intervention, and trial protocol 
are published elsewhere.15 The Newhints strategy was 
implemented in seven districts of the rural Brong Ahafo 
Region in western Ghana. The intervention consists of 
training an existing group of lay community health 
workers—community-based surveillance volunteers—to 
identify pregnant women in their com munities and to do 
two home visits during pregnancy and three visits on days 
1, 3, and 7 post partum. Each visit has a speciﬁ c purpose 
and, taken together, they aim to improve delivery and 
newborn care practices and careseeking for sick newborn 
babies.15 In each intervention community, at least one 
community-based surveillance volunteer (N=406) was 
fully trained in 2008 to undertake the Newhints 
intervention in addition to their existing activities. An 
additional 49 volunteers were trained in June, 2009, to 
replace 17 volunteers who resigned and to support 
implementation in communities with the highest 
workloads.15 Implementation and management of the 
strategy was led by Kintampo Health Research Centre 
(KHRC), a part of the Ghana Health Service, in close 
collaboration with seven district health management 
teams and the London School of Hygiene & Tropical 
Medicine (LSHTM). Two supervisors in each district 
health management team provided direct supervision 
and support to the community-based surveillance 
volunteers.
The combined population of the seven study districts, 
which comprised about 770 000 people,16 including more 
than 120 000 women of reproductive age and more than 
15 000 annual births, was divided into 98 supervisory 
zones of which half received the intervention. 
Surveillance data were collected monthly from every 
woman of reproductive age in the study area until June, 
2009, and every second month from pregnant women 
and infants from July, 2009, until March, 2010 
(appendix). The neonatal mortality rate at baseline 
(2005–07) was 32·7 deaths per 1000 livebirths in the 
control zones and 32·3 deaths per 1000 livebirths in the 
Newhints zones. In July, 2008, the Ghana National 
Health Insurance Scheme eliminated user fees for 
antenatal, intrapartum, postpartum, and newborn care 
in public, private, and mission facilities.17 Subsequently, 
the rate of facility-based births increased by 7·5%,17 but 
was similar between the Newhints and control zones 
(68·7% vs 68·4%) in 2009.3
See Online for appendix
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The ethics committees of the Ghana Health Service, 
KHRC, and LSHTM approved the study protocol.15 
Informed consent to use women’s surveillance data and, 
separately, permission to make home visits, were sought 
as previously described.3 Our methods and results are 
reported in accordance with the consolidated health 
economic evaluation reporting standards (CHEERS).18
Framing of the costing study
We estimated the incremental ﬁ nancial and economic 
costs of implementing the Newhints intervention, 
beyond those incurred by existing practice. Financial 
costs indicate the additional funding needed to pay for 
the intervention. Economic costs indicate the value 
(opportunity cost) of all resources used to implement 
Newhints, irrespective of whether they incurred a 
ﬁ nancial cost. Research costs were excluded. Activities 
that would continue after the intervention trial but might 
be reduced in intensity (eg, direct observation of home 
visits by supervisors) were included as intervention costs. 
The costs of extensive formative research activities 
undertaken during the setup period to design and 
develop the intervention, including manuals, workbooks, 
counselling cards, and the supervisory system, are 
presented separately on the understanding that the 
degree to which they would need to be repeated elsewhere 
would depend on the similarity of other contexts to the 
Brong Ahafo Region.
In the pre-implementation period, which began in 
October, 2006, activities were undertaken to design and 
set up the intervention (appendix). Full implementation 
began after refresher training in October, 2008. Additional 
management strategies were introduced between 
February and May, 2009, to improve coverage of home 
and supervisory visits. The 12 month period from January 
to December, 2009, was deﬁ ned as the implementation 
period over which annual running costs were calculated.
The analytical perspective is that of the public provider. 
Household costs (eg, time taken to receive the 
community-based surveillance volunteers at home, 
transport costs when seeking care) were not included, 
but were expected to be low, because a home visit to 
discuss newborn health and assess the babies is unlikely 
to represent a substantial opportunity cost for new 
mothers at home with their babies in the ﬁ rst week after 
birth. We included all costs incurred from the level of the 
community to the district health management team.
We assessed both the direct costs of implementing the 
intervention and the indirect costs, deﬁ ned here as 
the costs of increased health-service use attributable to 
the intervention.
Direct, indirect, and baseline intervention costs
We assessed the direct costs of implementing the 
intervention by collecting data retrospectively for the 
setup period and prospectively from October, 2008, 
onwards (appendix) using an ingredients approach in an 
adapted version of the Costs of Integrated Newborn Care 
Tool, developed by the South African Medical Research 
Council and the Africa Newborn Network.19 We extracted 
cost data from project accounts, interviews with project 
staﬀ , and discussions with the district health 
management team members. We obtained additional 
data about resource use from the surveillance system,3 a 
staﬀ  time-use study, and qualitative interviews. Costs 
indicated resources used to set up and implement home 
visits: capital equipment, human resources (community-
based surveillance volunteers, supervisors, and 
researchers’ time spent managing and supervising 
implementation), overheads, supplies, and the costs of 
meetings and trainings on home visits. The appendix 
provides further details of costing methods.
We deﬁ ned indirect costs as the costs of increased health-
service use attributable to the intervention. The Newhints 
trial provided no evidence that the intervention led to an 
increase in antenatal-care attendance or facility-based 
births.3 However, ﬁ ndings showed a statistically signiﬁ cant 
increase in the rate of care-seeking for newborns perceived 
to be ill (p=0·001)3 and very high rates of compliance with 
referrals by community-based surveillance volunteers 
(86% taken to a health facility, 73% taken to hospital).20 We 
estimated the cost of this additional facility attendance by 
combining Ghana National Health Insurance Scheme 
diagnosis-related group reimbursement rates for newborn 
consultations and causes of admission with estimates of 
the incremental number of sick newborn visits attributable 
to the Newhints intervention, and with data for the rate 
and types of admissions among newborn babies for whom 
care was sought.
Separately from our assessment of the direct and 
indirect costs of implementing home visits, we also 
estimated the costs of training in essential newborn care, 
which was done during the setup period. This training 
was provided to health facilities serving both control and 
intervention zones; therefore, its eﬀ ects on health 
outcomes, if any, could not be assessed in the trial and its 
costs were not included in the analysis of the incremental 
cost-eﬀ ectiveness of Newhints.
Statistical analysis
We analysed costs by type of input and by output. The total 
direct economic costs of implementation in 2009 were 
calculated as the sum of the economic running costs in 
2009 and the annualised setup costs. We used a discount 
rate of 3%, consistent with standard practice. We evaluated 
the useful life of vehicles on the basis of estimates used in 
a previous analysis of integrated management of 
childhood illness;21 estimates for equipment were made by 
the study team. Setup costs were annualised over a period 
of 10 years. Whereas the initial training of community-
based surveillance volunteers was included in setup costs, 
the cost of training newly recruited (replacement) 
volunteers and of ongoing training for all volunteers was 
included within recurrent costs.
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We present the aggregate ICER as the cost per newborn 
life saved and per discounted life-year saved. We 
calculated the ICER per newborn life saved by dividing 
the direct and indirect incremental economic costs of the 
intervention in 2009 (including annual running costs, 
discounted annualised setup and capital costs, and 
incremental costs to health facilities) by the estimated 
number of newborn lives saved in the intervention zones 
compared with the control zones during the same period. 
The number of newborn lives saved was modelled as the 
product of the number of livebirths in the intervention 
zones, the neonatal mortality rate in the control zones, 
and the protective eﬀ ectiveness of the intervention:
where CD is discounted total direct economic costs, CI is 
indirect economic costs, NIntervention is the number of 
livebirths in the intervention area, NMRControl is the neonatal 
mortality rate in the control areas, and PE is the protective 
eﬀ ectiveness (risk ratio) of the intervention. Because birth 
surveillance in the second half of 2009 was less frequent 
than in the ﬁ rst half of the year and underestimated the 
total number of births, we used data for the 12 month 
period from July, 2008, to June, 2009, to estimate the total 
number of births in 2009. Our base-case analysis used the 
protective eﬀ ectiveness estimate from the Newhints trial, 
which was modelled with random-eﬀ ects logistic 
regression to account for clustering.3 We calculated the 
number of life-years saved with a 3% discount rate, no age 
weighting, and Ghana’s life expectancy at birth in 2010 of 
65 years (95% CI 62·6–67·3; appendix).22 Our estimate of 
life-years saved corresponds to the years of life lived 
component of disability-adjusted life-years (DALYs).
We did deterministic one-way sensitivity analyses and 
probabilistic sensitivity analysis (ie, Monte Carlo 
simulation). In the probabilistic sensitivity analysis, we 
used 10 000 iterations per analysis and produced a mean 
point estimate by dividing mean costs by mean eﬀ ects 
and a 95% CI for the ICER based on percentiles. With a 
decision analytical model, we calculated the probability 
that the intervention would be cost eﬀ ective for various 
standard thresholds of cost-eﬀ ectiveness. For thresholds 
based on gross domestic product (GDP) per person, we 
used data for 2009, the year of implementation. We 
included Ghana’s own GDP per person in addition to the 
averages across low-income countries and lower-
middle-income countries to provide wider context and 
also because the 37% real-terms increase in Ghana’s 
GDP per person between 2009 and 2012 led the World 
Bank to change its classiﬁ cation from low-income to 
lower-middle-income in 2011.23
As well as our base-case analysis of the costs and eﬀ ects 
in the Newhints trial, we also did a series of scenario 
analyses to estimate the potential cost-eﬀ ectiveness of the 
newborn home-visit intervention in contexts with a range 
of underlying newborn mortality rates. Because there was 
no evidence of heterogeneity in eﬀ ect between Newhints 
and three studies of newborn home-visit interventions in 
south Asia, despite substantial diﬀ erences in baseline 
newborn mortality rates and other factors,3 we used the 
meta-analysis of the eﬀ ectiveness of newborn home visits 
in our scenario modelling. We combined our estimate of 
the costs of Newhints with a pooled eﬀ ectiveness estimate 
produced in the meta-analysis of all four trials of newborn 
home-visit interventions at scale and examined the cost-
eﬀ ectiveness at newborn mortality rates ranging from 
20 to 60 deaths per 1000 livebirths.
We did analyses in Excel with Visual Basic for 
Applications (version 6.5). All costs were converted into 
constant 2009 Ghana cedis (GH¢) using Ghana’s 
consumer price index,24 and then converted into constant 
2009 US$, in which ﬁ ndings are reported, based on the 
average 2009 exchange rate.25
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation or writing of 
the report. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
In the 49 zones randomly assigned to receive the Newhints 
intervention, there were at least 7848 pregnancies 
resulting in 7786 livebirths in the 12 months from July, 
2008, to June, 2009 (appendix). In these zones, which 
represent half the area and population of the seven 
districts, there was a mean of 407 (SD 18) community-
based surveillance volunteers, who undertook a 
(conservatively) estimated 19 546 home visits in 
189 communities in 2009, under the supervision of 
14 supervisors. An estimated 6054 (77%) mother-child 
pairs received at least one visit, and 1614 (21%) received 
the full package of ﬁ ve visits in 2009. Each community-
based surveillance volunteer did a mean of 4·0 visits 
per month, each of which lasted a mean of 80 min (SD 38).
The total ﬁ nancial and economic costs of providing 
essential newborn care training in October, 2008, for the 
ten largest health facilities, which serve both control and 
intervention zones, was $7625. The total ﬁ nancial cost of 
implementing the Newhints intervention was estimated 
to be $850 241. The extensive formative research 
undertaken to design the intervention accounted for a 
third of this total and the combination of set-up and 
capital accounted for another third (table 1). In 2009, the 
recurrent ﬁ nancial cost of implementation was $163 200 
(table 1). The economic cost of implementation in 2009, 
including the annualised costs of setup and capital, was 
$203 998. Of this total, human resources accounted for 
73% and capital accounted for 15% (table 1).
The community-based surveillance volunteers re-
ceived monthly incentives of ¢5 ($3·49) in addition to 
ICER per newborn
life saved
CD + CI
NIntervention×NMRControl×PE 
=
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payments for participation in initial and refresher training, 
and 25% of volunteers received a bonus payment of $3·49 
for good performance in late 2009. Because community-
based surveillance volunteers averaged only 4·0 home 
visits per month and could plan visits at their own 
convenience and in their own village, the work did not 
reduce their participation in other productive activities. 
Key informant interviews (n=3) and review of process 
evaluation results (unpublished) also indicated that, in the 
time they spent implementing Newhints, community-
based surveillance volunteers could not have generated 
more income from other activities than the payments they 
received for their participation in Newhints. The payments 
were therefore considered to represent both the ﬁ nancial 
and the economic cost of volunteers’ time. Each 
community-based surveillance volunteer also received a 
package of materials that included both equipment and 
supplies, for which the total annualised economic cost is 
estimated to be $19·45 (appendix).
The estimated total implementation cost per home visit 
in 2009 was $10·44 (appendix). For each mother-baby 
pair visited at least once, the cost of the intervention was 
$33·70, whereas the cost per pair receiving all ﬁ ve 
intended visits was $126·43. The cost per person (all 
ages) in the intervention area was $0·53.
The incremental cost of care-seeking for sick newborn 
babies attributable to the intervention was $6601, which 
represents a 3% increase in total costs beyond the 
annualised direct cost of implementing Newhints. On 
the basis of diagnosis-related group reimbursement 
rates, each newborn admission cost the health service 
$64, or $5228 for the estimated 82 additional newborn 
admissions attributable to Newhints. At $3·42 per 
newborn baby, the cost of the estimated 401 additional 
babies consulted as outpatients was substantially lower 
($1374) than the cost of newborn admissions (appendix).
In the probabilistic analysis of our base case, the mean 
incremental cost per newborn life saved was $10 343 
(95% CI 2963 to –$7674). Because the 95% CI for the 
eﬀ ectiveness estimate for the Newhints trial alone 
includes zero and negative health eﬀ ects, the conﬁ dence 
interval for the ICER also includes inﬁ nite and negative 
values, meaning that costs could be incurred but result 
in zero or negative health beneﬁ ts (ﬁ gure 1). By 
incorporation of Ghana’s life expectancy at birth, the 
ICER can also be expressed as $352 (95% CI 104 to –268) 
per discounted life-year saved.
Individually, most uncertain variables and 
assumptions have a fairly small eﬀ ect on the overall 
ICER (ﬁ gure 2). By contrast, uncertainty surrounding 
the discount rate, for which we consider a plausible 
 Figure 1: Cost-eﬀ ectiveness plane showing the statistical uncertainty around estimates of incremental costs 
and incremental life-years saved in the Newhints trial
Each grey dot represents the results of one of the 10 000 simulations. The incremental cost-eﬀ ectiveness ratio 
(ICER) for each simulation is deﬁ ned as the slope of the line from the origin to that datapoint. The large dot 
represents the mean ICER ($352 per life-year saved) at a mean cost of $212 009 and a mean of 602 years of life lost 
averted. Dashed lines demarcate the 2·5th and 97·5th percentiles used to estimate the 95% CI for the ICER. Since 
$352 per life-year saved lies northeast of the origin and is a positive number, indicating that (positive) costs will be 
incurred for a positive health gain. Datapoints falling northwest of the origin indicate the possibility that (positive) 
costs will be incurred for negative health gain (ie, health loss). For datapoints closest to or on the y-axis, costs 
remain positive, but the health eﬀ ects approach zero, and so the slope of the line which deﬁ nes the ICER 
approaches inﬁ nity.
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 Pre-implementation Implementation Total 1 year costs, 2009*
Design Setup and capital 2008† 2009 Economic Cost proﬁ le (%)
Financial Annualised 
economic
Financial Annualised 
economic
Financial Economic Financial Economic
Capital 0 473 199 064 1022 0 19 911 0 29 203 30 225 14·8%
Human resources 262 342 27 304 43 832 5455 80 011 80 011 144 414 144 414 149 870 73·5%
Meetings and training 7587 889 32 840 3850 3164 3164 2985 2985 6835 3·4%
Supplies 8059 945 3616 995 10 971 10 971 11 931 11 931 12 926 6·3%
Overheads 8059 166 2328 273 1514 1514 3870 3870 4143 2·0%
Total 279 407 29 778 281 680 11 596 95 661 115 573 163 200 192 403 203 998 100·0%
Design and setup costs are annualised over a period of 10 years, because ongoing training for existing and new staﬀ  is included in implementation costs. The ﬁ nancial costs of 
capital indicate the full costs of purchasing the items (mainly motorcycles and vehicles) at the start of the intervention, whereas the annualised economic costs indicate only 
the proportion of the time the items were used for implementation of the Newhints intervention (rather than for research activities or other projects), annualised over their 
expected useful life. *2009 implementation and annualised setup. †Pregnancy visits began in March, 2008, postnatal visits began in July, 2008, and full implementation 
began in November, 2008; the 2008 costs therefore do not represent 12 full months of implementation.
Table 1: Financial and economic costs (in 2009 US$) of implementation of the Newhints intervention
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 Figure 3: Cost-eﬀ ectiveness acceptability curves
Newhints trial (A). Scenarios with diﬀ ering NMRs (in deaths per 1000 livebirths) based on eﬀ ectiveness results in meta-analysis (B). LICs=low-income countries. 
LMICs=lower-middle-income countries. NMR=neonatal mortality ratio. DALY=disability-adjusted life-year. *Assuming a willingness-to-pay threshold.
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Figure 2: Tornado diagram of the percentage change in the base-case incremental cost-eﬀ ectiveness ratio (ICER) produced from a deterministic one-way 
analysis o f key input variables
Dark blue bars indicate the direction and magnitude of change of the ICER when the given input variable is at its minimum plausible value, whereas light blue bars 
indicate the direction and magnitude of change of the ICER when the same input variable is at its maximum plausible value. Variables listed towards the top of the 
diagram contribute more to the overall uncertainty in the cost-eﬀ ectiveness ratio than do those towards the bottom, which contribute relatively little to the 
uncertainty in the cost-eﬀ ectiveness ratio. The contribution of the protective eﬀ ectiveness to uncertainty in the ICER is understated—a range of 5–18% was used 
rather than the 95% CI from the Newhints trial of –12 to 25, because the resulting negative ICER could not be presented in this ﬁ gure.
–75 –50
–56·7 107·5
–55·6 60·0
–46·9 59·5
–24·2 24·2
–9·4 11·4
–4·6 14·7
–5·0 11·9
0 14·1
–1·6 11·1
–3·2 3·1
–1·1 1·2
–25 0 25 50 75 100 125
Discount rate
Protective eﬀectiveness
Neonatal mortality rate in control areas
Total direct costs of implementation of Newhints
Share of staﬀ time devoted to intervention
Number of births in the intervention area
Exchange rate (GH¢ to US$)
Design costs included with setup
Lifespan of setup activities
Incremental number of sick newborn babies taken to facility
Life expectancy of newborn babies
Percentage change
Articles
www.thelancet.com/lancetgh   Vol 4   January 2016 e51
range to lie between 0·01% and 7%, leads to variations 
in the ICER of –56% to 107%, or $161 to $769 per-
life year saved (appendix). Our one-way analysis also 
shows that, with all other variables held constant, the 
ICER would be 60% higher at a newborn mortality rate 
of 20 deaths per 1000 livebirths and 56% lower at a rate 
of 60 deaths per 1000 livebirths. Uncertainty regarding 
the eﬀ ectiveness of the intervention and, to a lesser 
extent, the total direct costs of implementing the inter-
vention, also had a pronounced eﬀ ect on the ICER, 
although these areas of uncertainty are incorporated 
into the probabilistic analyses.
Figure 3 shows the probability that the Newhints 
intervention was cost eﬀ ective with respect to eight 
diﬀ erent thresholds. The two lowest thresholds are the 
often-cited deﬁ nitions of very attractive and attractive 
interventions for low-income countries, originally 
expressed in 1993 as $25 per DALY averted for very 
attractive and $150 per DALY averted for attractive,26 and 
here updated to 2009 values of $37 and $223, respectively 
(ﬁ gure 3). The remaining six thresholds correspond to 
those used by WHO-CHOICE, which classiﬁ es 
interventions that cost less than per-person GDP per DALY 
averted as cost eﬀ ective, and those that cost less than three 
times per-person GDP per DALY averted as highly cost 
eﬀ ective.27 We show the two WHO thresholds based on the 
GDP per person as of 2009 in Ghana, low-income countries, 
and lower-middle-income countries (ﬁ gure 3).23 Although 
the Newhints intervention has only a 31% probability of 
being attractive with respect to the 1993 threshold of $150 
($223), it has a 72% chance of being highly cost eﬀ ective 
and a 78% chance of being cost eﬀ ective with respect to 
Ghana’s GDP per person in 2009 (ﬁ gure 3).
In our scenario analyses, we considered baseline 
neonatal mortality rates ranging from 20 to 60 deaths per 
1000 livebirths and used the eﬀ ectiveness estimate 
produced in the meta-analysis, which has both a slightly 
higher mean and a substantially narrower conﬁ dence 
interval than the Newhints trial alone (ﬁ gure 4). Under 
all scenarios, the home-visit strategy would have at least a 
99% probability of being highly cost eﬀ ective with respect 
to the per-person GDP of Ghana and of lower-middle-
income countries (ﬁ gure 3). Compared with the average 
per-person GDP for low-income countries, the strategy 
would also have a 99% probability of being highly cost 
eﬀ ective at neonatal mortality rates of 40 or more deaths 
per 1000 livebirths, whereas the probability would decline 
to 95% at a rate of 30 deaths per 1000 livebirths, and to 
76% at a rate of 20 deaths per 1000 livebirths (ﬁ gure 3). 
None of the scenarios would be deﬁ ned as very attractive 
with respect to the $37 threshold; however, the scenarios 
for baseline neonatal morality rates of 40, 50, and 
60 deaths per 1000 livebirths would have probabilities of 
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 Figure 4: Cost-eﬀ ectiveness planes for a meta-analysis of eﬀ ectiveness 
applied to ﬁ ve scenarios for the NMR (in deaths per 1000 livebirths)
NMR=neonatal mortality rate.
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68%, 86%, and 93%, respectively, of being considered 
attractive by costing less than $223 per DALY averted. 
With an ICER of $379 (95% CI 227–873) per life-year 
saved, the scenario with a baseline neonatal mortality 
rate of 20 deaths per 1000 livebirths would still be 
considered highly cost-eﬀ ective with respect to the 
average GDP per person for lower-middle-income 
countries if costs were 3·7 times greater than our 
estimates for Ghana’s Brong Ahafo Region (table 2).
Discussion
Although ﬁ ndings from the meta-analysis showing that 
newborn home visits reduced neonatal mortality by only 
12% in programme settings seemed modest and 
disappointing,35 such a reduction represents saving 290 000 
(95% CI 121 000–435 000) of the 2·4 million newborn 
babies1 who die in low-income and lower-middle-income 
countries every year, and our ﬁ ndings show that doing so 
could be highly cost-eﬀ ective. On the basis of our trial 
evidence alone, the Newhints newborn home-visit strategy 
has a 72% chance of costing less than Ghana’s per-person 
GDP per DALY averted and therefore being considered 
highly cost-eﬀ ective. There is thus only a 28% chance that 
not implementing the strategy would be the more cost-
eﬀ ective decision, based on this threshold and taking into 
account the uncertainty in the Newhints trial eﬀ ectiveness 
estimate and other variables.36 Furthermore, our scenario 
modelling, which incorporates meta-analysis ﬁ ndings of 
the eﬀ ectiveness of home visits, shows that the Newhints 
newborn home-visit strategy has more than a 95% chance 
of being highly cost-eﬀ ective in settings with a neonatal 
mortality rate of 30 or more newborn deaths per 
1000 livebirths and similar health-system factors, even if 
the threshold is set as low as the average per-person GDP 
of low-income countries.
The key drivers of cost-eﬀ ectiveness in our analysis 
were assumptions regarding the discount rate and 
uncertainty around the protective eﬀ ectiveness, baseline 
neonatal mortality rate, and implementation costs. 
However, the transferability of our cost-eﬀ ectiveness 
results to other areas of Ghana or of other countries will 
also depend substantially on the degree of similarity in 
the existing health system (Vassall A, London School of 
Hygiene & Tropical Medicine, personal communication). 
We would therefore expect some areas of Ghana, notably 
Accra, to diﬀ er in too many relevant ways for our ﬁ ndings 
Strategy Location ICER (constant 2009 US$ per life-
year saved)
Neonatal mortality 
rate in control 
group (deaths per 
1000 livebirths)
Protective 
eﬀ ectiveness (%)
Newhints (this study) Newborn home visits Brong Ahafo, Ghana 352 (104 to –268) 32 8 (–12 to 25)
Newhints (this study) Newborn home visits (Modelling) 379 (227 to 873) 20 12 (5 to 18)
Newhints (this study) Newborn home visits (Modelling) 256 (154 to 577) 30 12 (5 to 18)
Newhints (this study) Newborn home visits (Modelling) 191 (114 to 428) 40 12 (5 to 18)
Newhints (this study) Newborn home visits (Modelling) 153 (91 to 344) 50 12 (5 to 18)
Newhints (this study) Newborn home visits (Modelling) 127 (75 to 284) 60 12 (5 to 18)
MaiMwana28 Women’s groups Mchinji, Malawi 112 30 41 (14 to 60)
Fottrell et al, 201329 Women’s groups Three districts, 
Bangladesh
Trial: 375
Straight to scale-up estimate: 249
30 38 (11 to 57)
Borghi et al, 200530 
Manandhar et al, 200431
Women’s groups Makwanpur, Nepal 248 37 29 (6 to 46)
LUNESP32,33 Training traditional birth 
attendants in newborn care
Lufwanyama, Zambia 168 40 45 (10 to 67)
LUNESP32,33 Training traditional birth 
attendants in newborn care
Modelling for 
Lufwanyama, Zambia
Base case: 71
Optimistic scenario: 23 Pessimistic 
scenario: 114
40 45 (10 to 67)
Projahnmo I14 Newborn home visits Sylhet, Bangladesh Provider: 102 per DALY (64 to 262)
Societal: 105 per DALY (65 to 267)
43 28
Tripathy et al, 201034 Women’s groups Jharkhand
and Orissa, India
34 59 33 (23 to 42)
Bang et al, 200513 Newborn home visits Gadchiroli, India 8 64 61 (44 to 73)
Data in parentheses show 95% CIs. The table presents the ICER of the Newhints intervention in Ghana, and our modelling of the ICER with the eﬀ ectiveness estimated by 
meta-analysis of four programmatic studies of newborn home-visit strategies. We compare our own ﬁ ndings with those of existing economic evaluations of 
community-based newborn health strategies in developing countries for which neonatal mortality was the primary endpoint. All ﬁ ndings are presented in the context of the 
neonatal mortality rate, which is a key determinant of the ICER, with published costs converted to constant 2009 US$. The protective eﬀ ectiveness of women’s groups in 
Nepal and India is calculated from the odds ratio presented in each study. All studies used a 3% discount rate for costs and eﬀ ects except for that by Bang et al,13 in which the 
discount rate was not stated. All studies took a provider perspective except for Projahnmo I,14 which took a societal perspective but showed that doing so only increased total 
costs by 1·1%. ICER=incremental cost-eﬀ ectiveness ratio. DALY=disability-adjusted life-year.
Table 2: Cost-eﬀ ectiveness in the Newhints trial and modelled scenarios, and comparison with economic evaluations of other community-based 
newborn health strategies
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to be considered transferable; however, our ﬁ ndings 
could be relevant both to many rural areas of Ghana and 
to rural areas of other countries sharing these and other 
key health system factors.
Our scenario modelling shows that the cost per life-year 
saved would be higher in settings with lower neonatal 
mortality rates if all other variables remain constant. To 
date, a home-visit strategy has not been implemented in 
any setting with a neonatal mortality rate of fewer than 
28 deaths per 1000 livebirths, or in a programme setting 
with a neonatal mortality rate of more than 49 deaths per 
1000 livebirths; therefore, interpretations for settings with 
rates outside this range should be made cautiously. 
Because the home-visit strategies target only a subset of 
neonatal disorders thought to account for a lower 
proportion of newborn deaths at lower neonatal mortality 
rates, the strategies could be expected to be less eﬀ ective 
at lower mortality rates. Stratiﬁ ed meta-regression of the 
eight existing studies did not, however, provide evidence 
of any meaningful association between baseline neonatal 
mortality rate and the percentage of mortality reduction 
achieved (appendix). Thus, at neonatal mortality rates of 
less than 28 deaths per 1000 livebirths, we might have 
overestimated the protective eﬀ ectiveness of the strategy, 
and thus also its cost-eﬀ ectiveness; without further data, 
however, it is impossible to know the neonatal mortality 
rate at which the eﬀ ectiveness of the home-visit strategy 
decreases substantially.
In Ghana, a 2011 survey covering the previous 10 years 
reported that the country’s average neonatal mortality 
rate was 32 deaths per 1000 livebirths and that this rate 
varied from 20 deaths in the Greater Accra capital region 
to 25 deaths in the second lowest mortality region, and 
up to 44 deaths in Brong Ahafo and 47 deaths in Volta, 
the highest mortality region.37 Variation is likely to be 
even wider at the district level. According to the most 
recent estimates, the neonatal mortality rate across all 
low-income and middle-income countries was 23 deaths 
per 1000 livebirths in 2012, compared with a rate of four 
deaths per 1000 livebirths in high-income countries.1 
11 countries had neonatal mortality rates of 40 or more 
deaths per 1000 livebirths, 15 countries had rates between 
30 and 40 deaths per 1000 livebirths, and 33 countries 
(including Ghana) had rates between 20 and 30 deaths 
per 1000 livebirths.38 The range of neonatal mortality 
rates assessed in our scenario analyses is therefore very 
pertinent for Ghana and potentially relevant to areas of 
other countries.
Nonetheless, further contextual factors should also be 
considered in assessment of if and how results in another 
setting might diﬀ er. Newhints was able to build on a pre-
existing group of lay health volunteers who were willing 
and able to expand their role and whom community 
members were willing to accept as counsellors in 
newborn care. Rates of key positive behaviours for 
newborn health, including facility-based births, were 
already fairly high at baseline, whereas the quality of 
newborn care in health facilities was poor.3,39 The cost of 
increased use of health facilities attributable to Newhints 
was extremely low because only a few babies for whom 
care was sought were admitted to hospital, and because 
in our setting, the strategy did not increase usage rates 
for other services. We used reimbursement rates from 
the Ghana National Health Insurance Scheme for the 
cost of each newborn consultation and admission, which 
should reﬂ ect the costs of good quality care (even if good 
care was not provided). Because the average cost of 
newborn admission ($64) is 19 times that of a consultation 
($3·42), admission of a greater proportion of newborn 
babies presenting at health facilities would quickly 
increase the costs of their care. Diﬀ erences in any of 
these or other underlying health system factors could 
aﬀ ect the costs, eﬀ ects, and cost-eﬀ ectiveness of the 
Newhints strategy in another setting
Modiﬁ cations to the intervention package could 
potentially increase the eﬀ ectiveness of the strategy or 
address diﬀ ering health-system constraints in another 
setting; however, such changes might also aﬀ ect the cost-
eﬀ ectiveness. A proposed strategy of combining home 
visits with more intensive activities to increase the quality 
of care for sick newborn babies in health facilities40 would 
increase the costs of implementation and incremental 
health-service use, but oﬀ ers the potential for synergistic 
increases in eﬀ ectiveness and possibly economies of 
scope, which, together, could lead to a more cost-eﬀ ective 
strategy. Similarly, extending the scope of the intervention 
package to include an increased emphasis on the 
mother’s health, especially in contexts with low rates of 
facility-based births, could increase the eﬀ ectiveness but 
also change the costs and cost-eﬀ ectiveness. Changes in 
the volunteer status, payment structure, or expected 
workload of individuals making the home visits could 
also aﬀ ect cost-eﬀ ectiveness.
Although the Newhints intervention was implemented 
in a programmatic setting, rather than a highly controlled 
eﬃ  cacy context, some aspects of the evaluation context 
might nonetheless have aﬀ ected our cost-eﬀ ectiveness 
estimates. First, our cost estimates were based on a 
setting in which only half the zones in each participating 
district received the intervention, whereas imple-
mentation in all zones would probably provide some 
economies of scale. Second, we might have overestimated 
the number of additional newborns for whom care was 
sought in the intervention zones because we assumed 
the same underlying true rates of severe illness in the 
control and intervention zones, whereas improved care 
practices in the Newhints zones is likely to have resulted 
in lower rates of severe illness. Third, our evaluation was 
done quite early in the life of the strategy, and costs 
would be expected to fall and eﬀ ectiveness could 
potentially increase as management strategies were 
optimised and became more eﬃ  cient over time. Finally, 
human resources accounted for 74% of annualised 
economic costs and more than half these costs reﬂ ected 
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the value of the time that research staﬀ  from KHRC and 
LSHTM spent ensuring eﬀ ective implementation of the 
intervention. Although the KHRC and LSHTM staﬀ 
were paid more than the DHMT staﬀ  who would be 
expected to take over their responsibilities, they were also 
more highly qualiﬁ ed and possibly more motivated. It 
cannot simply be assumed that DHMT staﬀ  could 
achieve the same quality of implementation at a lower 
cost than the more highly paid researchers.
We compared our ﬁ ndings with other economic 
evaluations of community-based newborn health 
strategies, including home visits, women’s groups, and 
training of traditional birth attendants (panel). The 
Newhints newborn home-visit strategy costs substantially 
more than the $8 per life-year saved (2009 US$) presented 
by Bang and colleagues for the ﬁ nal years of the proof-of-
principle study in Gadchiroli, India.13 This diﬀ erence in 
cost is unsurprising because not only did the Gadchiroli 
study estimate a dramatic 60% reduction in neonatal 
mortality from an extremely high baseline of 62 deaths 
per 1000 livebirths, but, as already discussed,30 the cost 
analysis provided little detail and omitted important cost 
components.
Additionally, the home-visit strategy is less cost eﬀ ective 
than the US$102 (95% CI 64–262, converted to constant 
2009 US$) per DALY averted estimated in the Projahnmo 
I trial in Sylhet, Bangladesh.14 In the Projahnmo I study, 
estimated implementation costs were higher than those 
in Newhints ($34 vs $26 per livebirth), which might be 
partly explained by the proof-of-principle approach and 
the inclusion of antibiotic treatment in the home-visit 
package. However, the neonatal mortality rate in control 
areas in Projahnmo I was substantially higher (43 deaths 
per 1000 livebirths), as was the estimate of protective 
eﬃ  cacy (28%) in the ﬁ nal 12 months of the trial. Although 
Projahnmo I took a societal perspective in addition to a 
provider perspective, the addition of some household 
costs increased the ICER by only 1·1%. Projahnmo I also 
used a model-based synthesis of their trial data with 
international data and expert opinion to estimate the 
years of life with disability averted in addition to the life-
years saved, but inclusion of years of life with disability 
only increased the number of DALYs averted by 0·6%.43 
These ﬁ ndings support our view that neither the 
inclusion of household costs nor the eﬀ ect on chronic 
morbidity and disability would substantially aﬀ ect our 
ﬁ ndings. 
Although the Projahnmo I investigators used 
probabilistic sensitivity analysis to construct a conﬁ dence 
interval for their ICER estimate (and was the only one of 
the seven trials reviewed here to do so), only the 
eﬀ ectiveness estimate and the 1·1% of total costs borne 
by households were allowed to vary probabilistically, so 
their conﬁ dence interval substantially underestimates 
uncertainty. Our modelling suggests that a newborn 
home-visit strategy is likely to oﬀ er a level of cost-
eﬀ ectiveness that is similar to that of the women’s group 
interventions assessed in India,34 Bangladesh,29 Nepal,30 
and Malawi,28 (summarised in a systematic review of 
women’s groups44) and to the training of traditional birth 
attendants in newborn care assessed in Zambia.32 When 
compared with health interventions for other groups, 
newborn home visits are likely to be less cost eﬀ ective 
than, for example, preventive malaria interventions such 
as insecticide-treated bed nets (median $27 per DALY 
[range 8–110]) or indoor residual spraying ($143 per 
DALY [135–150]),45 but far more cost eﬀ ective than many 
interventions already implemented, such as those aiming 
to prevent and treat HIV.
By contrast with the more pessimistic interpretation of 
the Projahnmo I trial in Bangladesh,14 our detailed cost 
analysis, together with the fact that nationwide expansion 
is proceeding, suggest that Newhints could be aﬀ ordable 
in Ghana. We estimated that implementation will cost 
$0·53 per person (all ages), representing 1·3% of Ghana’s 
Government health expenditure in 2009 ($40 per person) 
and 0·9% of the 2011 expenditure of $57 per person.46 
Although district health budgets are substantially lower 
than general government health expenditure,47 these 
ﬁ gures suggest that, especially in view of a rapidly 
increasing GDP per person and government spending on 
health,23 Ghana might have scope to adopt a national 
newborn home-visit strategy. Aﬀ ordability in other 
countries will depend on the level of general government 
health expenditure, which varies tremendously even 
between countries of similar income levels. With the 
assumption of constant costs, implementation would 
represent 5·3% of the average government health 
expenditure for low-income countries in 2009 and 2·3% 
for lower-middle-income countries.46 Because capital 
costs accounted for 15% of annualised overall costs 
(which is unusually high for a community-based 
Panel: Research in context
Systematic review
A 2014 systematic review41 analysed the cost-eﬀ ectiveness of strategies to improve the 
use and provision of maternal and newborn health care in low-income and 
lower-middle-income countries. The search included literature published between 
January, 1990, and October, 2013. We focused on the subset of seven articles identiﬁ ed in 
the review that produced novel estimates of the incremental cost-eﬀ ectiveness ratio for 
community-based strategies to improve newborn health: the two previous economic 
evaluations of home visits, four primary economic evaluations of women’s groups, and 
an economic evaluation of training traditional birth attendants.
Interpretation
Our study makes an important contribution to a very small evidence base as Ghana and 
other highly resource-constrained countries decide if and how to implement or continue 
home visits for newborn babies. Our study also contributes to wider, complex debates 
about the roles of community health workers and community-based care.42 We show that 
the seemingly modest mortality reductions achieved by a newborn home-visit strategy 
can in fact be highly cost eﬀ ective. In Ghana, such strategies are also likely to be 
aﬀ ordable. Our ﬁ ndings support recommendations from WHO and UNICEF that 
low-income and middle-income countries implement newborn home visits.
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intervention), provision for substantial upfront ﬁ nancial 
costs would need to be included in the budget for future 
implementation. The motorcycles and vehicles making 
up these capital costs, and their ongoing maintenance, 
played an important part in eﬀ ective supervision and thus 
the eﬀ ectiveness of the intervention.
Our study has some other limitations. We took a 
provider perspective, and so did not include household 
costs associated with the intervention. However, we have 
shown that even if costs were several times higher, the 
intervention would still be considered highly cost 
eﬀ ective. Estimation of the proportion of time contributed 
to the intervention by staﬀ  engaged in a range of activities 
was also particularly challenging and subject to 
uncertainty. Our methods for data collection and analysis 
have, we believe, largely captured this uncertainty in our 
estimates, although we could have underestimated this 
uncertainty. Finally, our trial measured mortality but not 
morbidity; however, because estimates suggest that 
inclusion of morbidity would have a negligible eﬀ ect on 
the DALYs averted by newborn home visits,43 we believe 
that our use of DALY-based thresholds for assessment of 
cost-eﬀ ectiveness remain broadly appropriate.
In conclusion, our ﬁ ndings support recommendations 
from WHO and UNICEF that low-income and middle-
income countries implement a newborn home-visit 
strategy. However, substantial variation exists across 
programmes in the health-worker proﬁ les, content of 
visits (preventive vs curative, newborn vs combined 
maternal and newborn care), and the combining of home 
visits with innovations to improve the quality of facility-
based care, making it challenging for policy makers to 
select the best programme design for their local health 
system and epidemiological context. Further research in 
this area should include economic analyses done with a 
consistent methodology to support decision making.
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